LY2599666 / Eli Lilly - LARVOL DELTA

Pharmacokinetics and Pharmacodynamics of LY2599666, a PEG-Linked Antigen Binding Fragment that Targets Soluble Monomer Amyloid-β. (PubMed, J Alzheimers Dis) - "In addition, single cerebrospinal fluid samples were collected to assess penetration capability across the blood-brain barrier. PK and PD data collected from the multiple dose cohort aligned with model predictions, suggesting the established TMDD model predicted suppression of soluble Aβ 40 and Aβ 42 in plasma after SC dosing of LY2599666."

Journal • PK/PD data • Alzheimer's Disease • CNS Disorders

A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD) (clinicaltrials.gov) - P1; N=130; Active, not recruiting; Sponsor: Eli Lilly and Company; Recruiting ➔ Active, not recruiting

Enrollment closed • Alzheimer's Disease • Biosimilar